It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hyperactivated ribosome biosynthesis is attributed to a need for elevated protein synthesis that accommodates cell growth and division, and is characterized by nucleomorphometric alterations and increased nucleolar counts. Ribosome biogenesis is challenged when DNA-damaging treatments such as radiotherapy are utilized. Tumor cells that survive radiotherapy form the basis of recurrence, tumor progression, and metastasis. In order to survive and become metabolically revitalized, tumor cells need to reactivate RNA Polymerase I (RNA Pol I) to synthesize ribosomal RNA, an integral component of ribosomes. In this study, we showed that following radiation therapy, tumor cells from breast cancer patients demonstrate activation of a ribosome biosynthesis signature concurrent with enrichment of a signature of Hedgehog (Hh) activity. We hypothesized that GLI1 activates RNA Pol I in response to irradiation and licenses the emergence of a radioresistant tumor population. Our work establishes a novel role for GLI1 in orchestrating RNA Pol I activity in irradiated breast cancer cells. Furthermore, we present evidence that in these irradiated tumor cells, Treacle ribosome biogenesis factor 1 (TCOF1), a nucleolar protein that is important in ribosome biogenesis, facilitates nucleolar translocation of GLI1. Inhibiting Hh activity and RNA Pol I activity disabled the outgrowth of breast cancer cells in the lungs. As such, ribosome biosynthesis and Hh activity present as actionable signaling mechanisms to enhance the effectiveness of radiotherapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
2 University of Alabama at Birmingham, Division of Preventive Medicine, Department of Medicine, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Center for Clinical and Translational Sciences, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
3 University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Division of Hematology Oncology, Department of Medicine, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
4 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); Birmingham VA Medical Center, Birmingham, USA (GRID:grid.280808.a) (ISNI:0000 0004 0419 1326)
5 University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)